565 related articles for article (PubMed ID: 28452038)
21. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
Pulsipher MA; Carlson C; Langholz B; Wall DA; Schultz KR; Bunin N; Kirsch I; Gastier-Foster JM; Borowitz M; Desmarais C; Williamson D; Kalos M; Grupp SA
Blood; 2015 May; 125(22):3501-8. PubMed ID: 25862561
[TBL] [Abstract][Full Text] [Related]
22. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.
Della Starza I; Chiaretti S; De Propris MS; Elia L; Cavalli M; De Novi LA; Soscia R; Messina M; Vitale A; Guarini A; Foà R
Front Oncol; 2019; 9():726. PubMed ID: 31448230
[No Abstract] [Full Text] [Related]
23. PCR Technology to Identify Minimal Residual Disease.
Cazzaniga G; Songia S; Biondi A;
Methods Mol Biol; 2021; 2185():77-94. PubMed ID: 33165844
[TBL] [Abstract][Full Text] [Related]
24. [Identification of immunoglobulin and T-cell receptor gene rearrangements--prerequisite for monitoring of minimal residual disease in Polish acute lymphoblastic leukemia patients based on European standards. Preliminary results].
Dawidowska M; Derwich K; Szczepański T; Jółkowska J; Witt M; Wachowiak J
Med Wieku Rozwoj; 2006; 10(1 Pt 2):323-34. PubMed ID: 17028396
[TBL] [Abstract][Full Text] [Related]
25. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
van der Velden VH; Cazzaniga G; Schrauder A; Hancock J; Bader P; Panzer-Grumayer ER; Flohr T; Sutton R; Cave H; Madsen HO; Cayuela JM; Trka J; Eckert C; Foroni L; Zur Stadt U; Beldjord K; Raff T; van der Schoot CE; van Dongen JJ;
Leukemia; 2007 Apr; 21(4):604-11. PubMed ID: 17287850
[TBL] [Abstract][Full Text] [Related]
26. How I investigate minimal residual disease in acute lymphoblastic leukemia.
Correia RP; Bento LC; de Sousa FA; Barroso RS; Campregher PV; Bacal NS
Int J Lab Hematol; 2021 Jun; 43(3):354-363. PubMed ID: 33423385
[TBL] [Abstract][Full Text] [Related]
27. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
[TBL] [Abstract][Full Text] [Related]
28. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.
van der Velden VH; Panzer-Grümayer ER; Cazzaniga G; Flohr T; Sutton R; Schrauder A; Basso G; Schrappe M; Wijkhuijs JM; Konrad M; Bartram CR; Masera G; Biondi A; van Dongen JJ
Leukemia; 2007 Apr; 21(4):706-13. PubMed ID: 17287857
[TBL] [Abstract][Full Text] [Related]
29. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
30. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle.
Brüggemann M; Gökbuget N; Kneba M
Semin Oncol; 2012 Feb; 39(1):47-57. PubMed ID: 22289491
[TBL] [Abstract][Full Text] [Related]
31. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
[TBL] [Abstract][Full Text] [Related]
32. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR.
van der Velden VH; van Dongen JJ
Methods Mol Biol; 2009; 538():115-50. PubMed ID: 19277574
[TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
34. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
35. High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.
Salson M; Giraud M; Caillault A; Grardel N; Duployez N; Ferret Y; Duez M; Herbert R; Rocher T; Sebda S; Quief S; Villenet C; Figeac M; Preudhomme C
Leuk Res; 2017 Feb; 53():1-7. PubMed ID: 27930944
[TBL] [Abstract][Full Text] [Related]
36. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
[TBL] [Abstract][Full Text] [Related]
37. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis.
van der Velden VH; Wijkhuijs JM; Jacobs DC; van Wering ER; van Dongen JJ
Leukemia; 2002 Jul; 16(7):1372-80. PubMed ID: 12094263
[TBL] [Abstract][Full Text] [Related]
38. A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.
Fries C; Burack WR
Leuk Res; 2018 Dec; 75():15-22. PubMed ID: 30445235
[TBL] [Abstract][Full Text] [Related]
39. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
40. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
